Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Multicenter, Two-arm Parallel, Open-label, Randomised Phase III Study to Explore the Efficacy and Safety of Cadonilimab Plus Chemotherapy After Short-course Radiotherapy in Locally Advanced Rectal Cancer

NCT06832917 is registered in ClinicalTrials.gov with Wan He as lead sponsor.

NCT NCT06832917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06832917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Multicenter, Two-arm Parallel, Open-label, Randomised Phase III Study to Explore the Efficacy and Safety of Cadonilimab Plus Chemotherapy After Short-course Radiotherapy in Locally Advanced Rectal Cancer
Lead sponsor
Wan He
Phase
Phase 3
Overall status
Not yet recruiting
Start date
March 31, 2025
Completion date
December 31, 2029
Enrollment
238 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer